Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, announced a research collaboration with Daiichi Sankyo through its Daiichi Sankyo...
Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced a collaboration with Daiichi Sankyo focused on a key neurodegeneration target.
Wayfinder's proprietary technology...
AMRA's recent research, performed in collaboration with Daiichi Sankyo and the National Center of Neurology and Psychiatry (NCNP) in Japan, will be presented at...
